Headlines about Allergan PLC. (NYSE:AGN) have trended somewhat positive on Monday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Allergan PLC. earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.5654675652312 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern’s rankings:
- Allergan PLC. (AGN) Given Average Rating of “Hold” by Brokerages (americanbankingnews.com)
- Allergan PLC. (AGN) versus NephroGenex (NRXGQ) Critical Survey (americanbankingnews.com)
- Is The Stock Risky? (Beta Analysis) – Allergan plc, (NYSE: AGN) – Stock Watch (stocksnewstimes.com)
- Allergan plc. (AGN) Ex-Dividend Date Scheduled for November 16, 2017 – Nasdaq (nasdaq.com)
- Generic Drugs Stock Performance Review — Catalyst Pharma, Flexion Therapeutics, Supernus Pharma and Allergan (bizjournals.com)
Shares of Allergan PLC. (AGN) traded down $3.91 on Monday, reaching $170.97. 2,220,355 shares of the company traded hands, compared to its average volume of 2,909,662. Allergan PLC. has a fifty-two week low of $169.61 and a fifty-two week high of $256.80. The firm has a market capitalization of $58,160.00, a PE ratio of 11.34, a price-to-earnings-growth ratio of 1.11 and a beta of 1.12. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Friday, November 17th will be paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 1.64%. The ex-dividend date is Thursday, November 16th. Allergan PLC.’s dividend payout ratio is currently -12.39%.
Allergan PLC. announced that its Board of Directors has approved a share repurchase plan on Monday, September 25th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to buy up to 2.8% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.
A number of equities analysts have weighed in on AGN shares. Citigroup Inc. reaffirmed a “buy” rating and issued a $280.00 target price on shares of Allergan PLC. in a research note on Wednesday, September 20th. Deutsche Bank AG set a $251.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a research note on Tuesday, October 17th. Piper Jaffray Companies set a $227.00 target price on shares of Allergan PLC. and gave the stock a “hold” rating in a research note on Friday, October 6th. J P Morgan Chase & Co reissued a “buy” rating and set a $275.00 price target on shares of Allergan PLC. in a research note on Monday, October 16th. Finally, Royal Bank Of Canada reissued a “buy” rating and set a $285.00 price target on shares of Allergan PLC. in a research note on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Allergan PLC. currently has a consensus rating of “Hold” and an average target price of $246.73.
TRADEMARK VIOLATION NOTICE: “Allergan PLC. (AGN) Earning Somewhat Favorable Media Coverage, Study Finds” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.com-unik.info/2017/11/20/allergan-plc-agn-earning-somewhat-favorable-media-coverage-study-finds.html.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
What are top analysts saying about Allergan PLC.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allergan PLC. and related companies.